Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8897701rdf:typepubmed:Citationlld:pubmed
pubmed-article:8897701lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:8897701lifeskim:mentionsumls-concept:C0812413lld:lifeskim
pubmed-article:8897701lifeskim:mentionsumls-concept:C0225778lld:lifeskim
pubmed-article:8897701lifeskim:mentionsumls-concept:C0814026lld:lifeskim
pubmed-article:8897701pubmed:issue2lld:pubmed
pubmed-article:8897701pubmed:dateCreated1997-3-4lld:pubmed
pubmed-article:8897701pubmed:abstractTextThe two major fibrinolytic activators, urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA) may play role in tumor spread and metastasis. Malign pleural mesothelioma (MPM) is a kind of tumor with predominantly local invasion and low incidence of distant metastasis. In this study, u-PA, t-PA and PA activator-1 (PAI-1) antigen and activity were measured in plasma and pleural fluid samples from patients with MPM, lung cancer and benign effusion. When compared to the control group, in MPM group, plasma u-PA and t-PA antigen levels were higher, but plasma u-PA and t-PA activity were comparable. PAI-1 antigen was also higher in MPM group. These findings were in contrast to the lung cancer group, in which both activity and immunologic measurement of u-PA and t-PA were higher, but PAI-1 antigen was similar as compared to the control group. It is concluded that excess t-PA and u-PA are balanced in complexes with PAI-1 in MPM, whereas the amount of PAI-1 in plasma is insufficient to overcome the elevated t-PA and u-PA, in lung cancer. Based on these findings, it may be suggested that the balanced fibrinolytic system is responsible for the low incidence of distant metastasis in MPM.lld:pubmed
pubmed-article:8897701pubmed:languageenglld:pubmed
pubmed-article:8897701pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8897701pubmed:citationSubsetIMlld:pubmed
pubmed-article:8897701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8897701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8897701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8897701pubmed:statusMEDLINElld:pubmed
pubmed-article:8897701pubmed:monthOctlld:pubmed
pubmed-article:8897701pubmed:issn0049-3848lld:pubmed
pubmed-article:8897701pubmed:authorpubmed-author:OzdemirOOlld:pubmed
pubmed-article:8897701pubmed:authorpubmed-author:DündarSSlld:pubmed
pubmed-article:8897701pubmed:authorpubmed-author:EmriSSlld:pubmed
pubmed-article:8897701pubmed:authorpubmed-author:Bari?IIlld:pubmed
pubmed-article:8897701pubmed:authorpubmed-author:AkayHHlld:pubmed
pubmed-article:8897701pubmed:authorpubmed-author:SayinalpNNlld:pubmed
pubmed-article:8897701pubmed:authorpubmed-author:KarakocaYYlld:pubmed
pubmed-article:8897701pubmed:issnTypePrintlld:pubmed
pubmed-article:8897701pubmed:day15lld:pubmed
pubmed-article:8897701pubmed:volume84lld:pubmed
pubmed-article:8897701pubmed:ownerNLMlld:pubmed
pubmed-article:8897701pubmed:authorsCompleteYlld:pubmed
pubmed-article:8897701pubmed:pagination121-8lld:pubmed
pubmed-article:8897701pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:8897701pubmed:meshHeadingpubmed-meshheading:8897701-...lld:pubmed
pubmed-article:8897701pubmed:meshHeadingpubmed-meshheading:8897701-...lld:pubmed
pubmed-article:8897701pubmed:meshHeadingpubmed-meshheading:8897701-...lld:pubmed
pubmed-article:8897701pubmed:meshHeadingpubmed-meshheading:8897701-...lld:pubmed
pubmed-article:8897701pubmed:meshHeadingpubmed-meshheading:8897701-...lld:pubmed
pubmed-article:8897701pubmed:meshHeadingpubmed-meshheading:8897701-...lld:pubmed
pubmed-article:8897701pubmed:meshHeadingpubmed-meshheading:8897701-...lld:pubmed
pubmed-article:8897701pubmed:meshHeadingpubmed-meshheading:8897701-...lld:pubmed
pubmed-article:8897701pubmed:meshHeadingpubmed-meshheading:8897701-...lld:pubmed
pubmed-article:8897701pubmed:meshHeadingpubmed-meshheading:8897701-...lld:pubmed
pubmed-article:8897701pubmed:meshHeadingpubmed-meshheading:8897701-...lld:pubmed
pubmed-article:8897701pubmed:meshHeadingpubmed-meshheading:8897701-...lld:pubmed
pubmed-article:8897701pubmed:meshHeadingpubmed-meshheading:8897701-...lld:pubmed
pubmed-article:8897701pubmed:year1996lld:pubmed
pubmed-article:8897701pubmed:articleTitleFibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma.lld:pubmed
pubmed-article:8897701pubmed:affiliationHacettepe University Medical School, Department of Internal Medicine, Ankara, Turkey.lld:pubmed
pubmed-article:8897701pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8897701lld:pubmed